National survey on the management and information practices of patients with wet AMD

Marie-Laure Le Lez (1), Bénédicte Briend (2), Hélène Massé (3), Eric Fourmaux (4), Pierre Griffon (5), Franck Rumen (6), Salomon-Yves Cohen (7). (1) Tours University Hospital, (2) OSIRIS - Centre Rétine Anjou - Angers, (3) Nantes University Hospital, (4) Centre Ophtalmologique Palais Gallien - Bordeaux, (5) Sainte-Marie Hospital - Paris, (6) Visiopole - La Rochelle, (7) Centre Ophtalmologique d'Imagerie et de Laser - Paris

Objective	Materials and methods
According to the WHO, AMD is the world's third leading cause of visual impairment and accounts for almost 9% of all causes of blindness. Our work aimed to collect information practices with	Two types of questionnaires, developed by a committee of seven ophthalmologists and a psychologist to collect data at one $(M + 1)$ or twelve $(M + 12)$ months after diagnosis. The assessed criteria focused on patient's profile, their management, their

a multicentric survey on patients suffering from wet AMD. treatment.


How do you evaluate the explanation **Did you research Do you think the injections will cure your disease?** M + 1 given on the treatment by a healthcare additional information professional, on a 10-point scale? about your treatment? M + 1 **M + 12** n = 186 Average: 6.7 6% 38 16% 40 22% 31 37% 28 30 23 20 20 15 57% 14 78% 84% 10 6 Yes Yes Yes No **No** 0 10 Do not know Do not know No Scale from 0:very insufficient to 10: very sufficient n = 198n = 193n = 45

M + 1 How many injections do you expect to receive in



Could you continue your treatment and monitoring at the same pace as for the

and the



Conclusion

This survey demonstrated a gap between the information provided by the medical staff from one side and the apprehension towards the injection and the patient's experience on the other.

Conflicts of interest : Le Lez, M-L. Novartis, Bayer / Masse, H. Novartis, Allergan, Bayer / Cohen, S-Y. Allergan, Bayer, Novartis, Roche, Théa, Tilak Healthcare / Briend, B. Novartis, Bayer, Allergan / Rumen, F. Novartis, Bayer / Fourmaux, E. Allergan, Bayer, Novartis

P-002

Acknowledgements to all participants of this survey, to Sirius-Customizer for the medical writing and to Bayer France for the institutional support